Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

AbCellera up on expanded antibody discovery pact with Regeneron

** Shares of Biotech co AbCellera Biologics Inc  ABCL.O  up
1.5% to $5.2 
    ** ABCL expands its existing multi-target antibody discovery
collaboration with Regeneron Pharmaceuticals  REGN.O  
    ** Under the expanded pact, ABCL to now discover therapeutic
antibodies for up to eight targets (from four targets
previously) selected by REGN 
    ** Regeneron has the right to develop and commercialize
therapeutic antibodies resulting from the collaboration, which
has been in effect since March 2020 
    ** AbCellera receives research payments and is eligible to
receive downstream clinical and regulatory milestone payments
and royalties on net sales of products 
    ** Including session's gain, stock down ~49% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))

Recent news on AbCellera Biologics

See all news